Literature DB >> 1348298

Diagnostic value of decreasing IgG, IgA, and IgM antibody titres after eradication of Helicobacter pylori.

T U Kosunen1, K Seppälä, S Sarna, P Sipponen.   

Abstract

Titres of antibody to Helicobacter pylori are known to fall with eradication of bacteria. To find out what degree of fall would reliably indicate eradication, 144 patients with Helicobacter pylori infection were given antimicrobial therapy for 2 weeks and then followed up at 6 weeks, 6 months, and 12 months with serological tests, bacterial cultures, and histological studies of gastric specimens. 6 weeks after treatment IgG titres had fallen by 20-30% irrespective of the success of bacterial eradication. In the 121 bacteria-negative patients the decrease continued. 6 and 12 months after treatment the titre was 50% or less of pretreatment value in 97% of these patients. In the 23 patients who remained infected, the initial drop of IgG titres, if any, was followed by unchanged or slightly rising titres. IgA and IgM titres, initially raised in 64% and 4% of the patients, respectively, showed similar trends. The high sensitivity (97%) of the IgG antibody tests and a consistent fall within 6 months after eradication of H pylori infection made IgG the most useful immunoglobulin class for follow-up of antimicrobial therapy in individual patients. IgA antibodies were valuable in the 2% patients who had raised titres in this immunoglobulin class only. The few patients (5.5%) who had raised IgM titres also had high IgG titres. Serological tests thus are a cheap and reliable means of monitoring success of eradication of H pylori.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1348298     DOI: 10.1016/0140-6736(92)90929-w

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  91 in total

Review 1.  Naturally acquired human immune responses against Helicobacter pylori and implications for vaccine development.

Authors:  Y Zevering; L Jacob; T F Meyer
Journal:  Gut       Date:  1999-09       Impact factor: 23.059

2.  Non-invasive testing for Helicobacter pylori.

Authors:  M A Stone
Journal:  Postgrad Med J       Date:  1999-02       Impact factor: 2.401

3.  Helicobacter pylori infection.

Authors:  Yvan Vandenplas
Journal:  World J Gastroenterol       Date:  2000-02       Impact factor: 5.742

Review 4.  Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group.

Authors: 
Journal:  Gut       Date:  1997-07       Impact factor: 23.059

Review 5.  An assessment of serological tests for detection of Helicobacter pylori.

Authors:  H von Wulffen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-07       Impact factor: 3.267

6.  Evaluation of a commercially available complement fixation test for diagnosis of Helicobacter pylori infection and for follow-up after antimicrobial therapy.

Authors:  H Goossens; Y Glupczynski; A Burette; C Van den Borre; C DePrez; J Bodenmann; A Keller; J P Butzler
Journal:  J Clin Microbiol       Date:  1992-12       Impact factor: 5.948

7.  Long-term semi-quantitative follow-up of Helicobacter pylori associated gastritis.

Authors:  T C Tham; J M Sloan; J S Collins
Journal:  Ir J Med Sci       Date:  1997 Jul-Sep       Impact factor: 1.568

8.  Case-control study of dietary pattern and other risk factors for gastric cancer.

Authors:  Ali Nemati; Reza Mahdavi; Abbas Naghizadeh Baghi
Journal:  Health Promot Perspect       Date:  2012-07-01

9.  Helicobacter pylori infection and low serum pepsinogen I level as risk factors for gastric carcinoma.

Authors:  Arto Kokkola; Johanna Louhimo; Pauli Puolakkainen; Henrik Alfthan; Caj Haglund; Hilpi Rautelin
Journal:  World J Gastroenterol       Date:  2005-02-21       Impact factor: 5.742

10.  Serum pepsinogens as a predicator of the topography of intestinal metaplasia in patients with atrophic gastritis.

Authors:  Yoshihisa Urita; Kazuo Hike; Naotaka Torii; Yoshinori Kikuchi; Eiko Kanda; Masahiko Sasajima; Kazumasa Miki
Journal:  Dig Dis Sci       Date:  2004-05       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.